Regency Capital Management’s BioNTech BNTX Stock Holding History

Regency Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-50	Closed	-$14K	–	130
2021 Q3	$14K	Buy	+50	New	+$15.9K	0.01%	106

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Regency Capital Management's BNTX Position: Q4 2021 in Review

Regency Capital Management sold out of BioNTech (BNTX) in Q4 2021, closing a stake of 50 shares — an estimated $14K sold.

Regency Capital Management first reported a position in BNTX in Q3 2021 and held it in 1 quarter. The position peaked at $14K in Q3 2021. 354 funds tracked by Wall St. Rank hold BNTX as of Q4 2021.

Regency Capital Management reported no remaining BioNTech position as of Q4 2021 after selling out during the quarter.
Regency Capital Management sold 50 BioNTech shares in Q4 2021, an estimated $14K.
Regency Capital Management first reported a position in BioNTech in Q3 2021 and held it in 1 quarter.
Regency Capital Management's BioNTech position peaked at $14K in Q3 2021.
354 funds tracked by Wall St. Rank held BioNTech as of Q4 2021.

Based on Regency Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.